ReviewNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2012
Strategies for the treatment of restless legs syndrome.
Review in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 2 syntheses or guidelines pooled it, 58 citations in OpenAlex.
- Efficacy of Pramipexole for the Treatment of Primary Restless Leg Syndrome: A Systematic Review and Meta-analysis of Randomized Clinical Trials.Clinical therapeutics · 2016Pooled it
- Survivorship: sleep disorders, version 1.2014.Journal of the National Comprehensive Cancer Network : JNCCN · 2014Guideline
- Trial
- Noninvasive neuromodulation reduces symptoms of restless legs syndrome.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2021Trial
- Feasibility and efficacy of a physical activity intervention for managing restless legs syndrome in multiple sclerosis: Results of a pilot randomized controlled trial.Multiple sclerosis and related disorders · 2021Trial
- Trial
- Observational
- Hydrotherapy and acupressure for restless legs syndrome: results of a qualitative part of a randomized controlled exploratory study.Frontiers in medicine · 2025Article
- Exploring the Top 50 Drugs Associated with Restless Legs Syndrome Based on the FDA Data from 2004 to 2024.Nature and science of sleep · 2025Article
- Efficacy of intravenous iron for restless legs syndrome-moving beyond monotherapy and into the "real world".Sleep · 2024Article
- Cost-Effectiveness of Tonic Motor Activation (TOMAC) Therapy for Patients with Restless Legs Syndrome: An Exploratory Analysis.Neurology and therapy · 2023Article
- Potential Effect of Vortioxetine on Restless Leg Syndrome.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2023Article
- Restless legs syndrome: An overview of pathophysiology, comorbidities and therapeutic approaches (Review).Experimental and therapeutic medicine · 2022Review
- Validity and reliability of the suggested immobilization test for measurement of restless legs syndrome severity in adults with multiple sclerosis.Sleep medicine · 2021Article
- Article
- Restless legs syndrome, sleep quality, and perceived cognitive impairment in adults with multiple sclerosis.Multiple sclerosis and related disorders · 2020Article
- Physical activity, sedentary behavior, and restless legs syndrome in persons with multiple sclerosis.Journal of the neurological sciences · 2019Article
- Restless legs syndrome secondary to pontine infarction: Clinical analysis of five cases.Chronic diseases and translational medicine · 2017Article
- Article
- The Berlin Treatment Algorithm: recommendations for tailored innovative therapeutic strategies for multiple sclerosis-related fatigue.The EPMA journal · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Restless legs syndrome (RLS) is a common neurological disorder of unknown etiology that is managed by therapy directed at relieving its symptoms. Treatment of patients with milder symptoms that occur intermittently may be treated with nonpharmacological therapy but when not successful, drug therapy should be chosen based on the timing of the symptoms and the needs of the patient. Patients with moderate to severe RLS typically require daily medication to control their symptoms. Although the dopamine agonists, ropinirole and pramipexole have been the drugs of choice for patients with moderate to severe RLS, drug emergent problems like augmentation may limit their use for long term therapy. Keeping the dopamine agonist dose as low as possible, using longer acting dopamine agonists such as the rotigotine patch and maintaining a high serum ferritin level may help prevent the development of augmentation. The α2δ anticonvulsants may now also be considered as drugs of choice for moderate to severe RLS patients. Opioids should be considered for RLS patients, especially for those who have failed other therapies since they are very effective for severe cases. When monitored appropriately, they can be very safe and durable for long term therapy. They should also be strongly considered for treating patients with augmentation as they are very effective for relieving the worsening symptoms that occur when decreasing or eliminating dopamine agonists.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.